TESARO (TSRO) Misses Q2 EPS by 39c, Cuts FY Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to TESARO (TSRO) Misses Q2 EPS by 39c, Cuts FY Revenue Guidance

TESARO Announces Second-Quarter 2018 Operating Results

August 2, 2018 4:05 PM EDT

ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017QUADRA sNDA submission planned for Q4 2018PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of biomarker status enrollment completedDivestiture completed for VARUBI in U.S. and Canada for $40 million plus potential milestone payments and royaltiesData expected from TSR-042 (anti-PD-1) GARNET NSCLC and MSI-high endometrial expansion cohorts in 2H 2018; regulatory submission planned for 2019

WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:... More